Evidence map›Paper›PMID 34712047›Full record

ArticleInternational journal of nanomedicine2021

Robust Immune Response Induced by

Mayra M F Barbosa, Alex I Kanno, Giovana C Barazzone, Dunia Rodriguez, Violeta Pancakova, Monalisa Trentini, Eliana L Faquim-Mauro, Amanda P Freitas, Mariana I Khouri, Jessica Lobo-Silva and 7 more

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 5 countries.

Mayra M F BarbosaLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.ORCID 0000-0003-3602-1279
Alex I KannoLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Giovana C BarazzoneLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.ORCID 0000-0001-8601-8452
Dunia RodriguezLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Violeta PancakovaLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Monalisa TrentiniLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Eliana L Faquim-MauroLaboratório de Imunopatologia, Instituto Butantan, São Paulo, Brazil.ORCID 0000-0001-8083-4272
Amanda P FreitasLaboratório de Imunopatologia, Instituto Butantan, São Paulo, Brazil.
Mariana I KhouriLaboratório de Biomarcadores e Inflamação, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.ORCID 0000-0003-4371-4241
Jessica Lobo-SilvaLaboratório de Biomarcadores e Inflamação, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Viviane M GoncalvesLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Rocilda P F SchenkmanLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Martha M TanizakiLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Diana BoraschiIstituto di Biochimica e Biologia Cellulare, Consiglio Nazionale delle Ricerche, Napoli, Italy.
Richard MalleyDivision of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Leonardo P FariasLaboratório de Biomarcadores e Inflamação, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Luciana C C LeiteLaboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
Instituto Butantan · BRFundação Oswaldo Cruz · BRBoston Children's Hospital · USUniversidade de São Paulo · BRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe use of adjuvants can significantly strengthen a vaccine's efficacy. We sought to explore the immunization efficacy of bacterial outer membrane vesicles (OMVs) displaying the MATERIALS AND

methodsOMVs were obtained from

resultsThe rRzvSmTSP-2 protein was successfully coupled to biotinylated OMVs and purified by size-exclusion chromatography. The OMV:rSmTSP-2 nanoparticles showed an average size of 200 nm, with zeta potential around - 28 mV. Mouse Bone Marrow Dendritic Cells were activated by the nanoparticles as determined by increased expression of the co-stimulatory molecules CD40 and CD86, and the proinflammatory cytokines (TNF-α, IL-6 and IL-12) or IL-10. Splenocytes of mice immunized with OMV:rSmTSP-2 nanoparticles reacted to an in vitro challenge with SmTSP-2 with an increased production of IL-6, IL-10 and IL-17 and displayed a higher number of CD4+ and CD8+ T lymphocytes expressing IFN-γ, IL-4 and IL-2, compared to mice immunized with the antigen alone. Immunization of mice with OMV:rSmTSP-2 induced a 100-fold increase in specific anti-SmTSP-2 IgG antibody titers, as compared to the group receiving the recombinant rSmTSP-2 protein alone or even co-administered with unconjugated OMV.

conclusionOur results demonstrate that the SmTSP-2 antigen coupled with OMVs is highly immunogenic in mice, supporting the potential effectiveness of this platform for improved antigen delivery in novel vaccine strategies.

Indexed as

Escherichia coliSchistosoma mansoniAnimalsBacterial Outer MembraneImmunityMiceMice, Inbred C57BLbiotin-avidin couplingnanoparticleOMVouter membrane vesiclesSchistosoma mansoniTSP-2 antigenvaccine

Identifiers

PMID34712047
PMCPMC8548026
OpenAlexW3207650390

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.